Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.54 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21302767 | 0.95 | DGKA (0.59) | DGKACASP2FAAHL3MBTL1DNM1 | |
| SCHEMBL8922042 | 0.91 | DGKA (0.67) | DGKACASP2FAAHL3MBTL1DNM1 | |
| SCHEMBL20856388 | 0.91 | DGKA (0.67) | DGKACASP2FAAHL3MBTL1DNM1 | |
| SCHEMBL8921826 | 0.91 | DGKA (0.67) | DGKACASP2FAAHL3MBTL1DNM1 | |
| SCHEMBL303966 | 0.91 | DGKA (0.67) | DGKACASP2FAAHL3MBTL1DNM1 | |
| SCHEMBL8921681 | 0.91 | DGKA (0.67) | DGKACASP2FAAHL3MBTL1DNM1 | |
| SCHEMBL8920345 | 0.91 | DGKA (0.67) | DGKACASP2FAAHL3MBTL1DNM1 | |
| SCHEMBL8920199 | 0.91 | DGKA (0.67) | DGKACASP2FAAHL3MBTL1DNM1 | |
| SCHEMBL23177551 | 0.89 | DGKA (0.56) | DGKACASP2FAAHL3MBTL1DNM1 | |
| SCHEMBL23599342 | 0.89 | CASP2 (0.64) | DGKACASP2FAAHL3MBTL1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547681-B2 | N-acylethanolamide derivatives and uses thereof | ELIEM THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210093589-A1 | N-ACYLETHANOLAMIDE DERIVATIVES AND USES THEREOF | ELIEM THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| WO-2018071679-A1 | N-ACYLETHANOLAMIDE DERIVATIVES AND USES THEREOF | CARNOT, LLC (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093589-A1 | N-ACYLETHANOLAMIDE DERIVATIVES AND USES THEREOF | FAAH, FAAH2, NAAA | DGKA 140/4885CASP2 3361/4885FAAH 1/4885 |
| US-11547681-B2 | N-acylethanolamide derivatives and uses thereof | FAAH, FAAH2, NAAA | DGKA 140/4885CASP2 3361/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.